EGFR and non-small cell lung carcinoma: In the FURLONG trial, furmonertinib showed improved efficacy over gefitinib, when used as a first-line treatment for Chinese patients with EGFR-mutant NSCLC, with an acceptable safety profile, with a PFS of 20.8 months (95% CI 17.8–23.5) in the furmonertinib group and 11.1 months (9.7–12.5) in the gefitinib group (HR 0.44, 95% CI 0.34–0.58; p < 0.0001) [48].